Card image cap
Glenmark launches first teneligliptin-pioglitazone FDC

Mumbai-based drugmaker Glenmark Pharmaceuticals has launched the first fixed dose combination (FDC) of teneligliptin and pioglitazone, two diabetes management drugs, for adults with uncontrolled Type 2 diabetes. Branded as Zita Plus Pio, the combination therapy was approved by the Drug Controller General of India on Monday and is the only available DPP4 and glitazone combination drug in India.

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment